prostaglandin E0

a main plasma metabolite of prostaglandin E1; structure given in first source

Also Known As:

PGE(0); PGE0

Networked: 5 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Lipids: 114793
- Fatty Acids: 27405
  - Unsaturated Fatty Acids: 8236
    - Eicosanoids: 3262
      - Prostaglandins: 17100
        Prostaglandins E: 2673
        Alprostadil: 3107
        prostaglandin E0: 5
    - Monounsaturated Fatty Acids: 676
      - Alprostadil: 3107
        prostaglandin E0: 5
Biological Factors: 2472
- Inflammation Mediators: 1113
  - Autacoids: 276
    - Eicosanoids: 3262
      - Prostaglandins: 17100
        Prostaglandins E: 2673
        Alprostadil: 3107
        prostaglandin E0: 5

Related Diseases

1.	Myocardial Infarction 11/01/1995 - "Reduction by prostaglandin E1 or prostaglandin E0 of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels." 11/01/1995 - "1. This study examined whether pretreatment of rabbits with infusions of prostaglandin E1 (PGE1) or prostaglandin E0 (PGE0) (which were terminated prior to the onset of ischaemia) reduce myocardial infarct size arising from coronary artery occlusion (60 min) and reperfusion (120 min). "
2.	Peripheral Arterial Occlusive Disease 1 01/01/1991 - "The biological activities of PGE0 may contribute to the in vivo effects of PGE1 in treatment of peripheral arterial occlusive disease, in particular at high-dose i.v. administration." 01/01/1991 - "Generation of PGE0 from infused PGE1 may contribute to the clinical efficacy of PGE1 in treatment of severe peripheral arterial occlusive disease." 01/01/1991 - "It is concluded that the beneficial effects of PGE1 in treatment of peripheral arterial occlusive disease are a multifactorial event and might involve PGE0, in particular at intravenous administration of high doses."
3.	Infarction (Infarctions) 11/01/1995 - "Similarly, glibenclamide also largely attenuated the reduction in infarct size afforded by PGE0 (52 +/- 3%; n = 8). " 11/01/1995 - "PGE1 or PGE0 treatment (1.0 micrograms kg-1 min-1), administered as 1 h pretreatments (0.05 ml min-1, i.v.), significantly reduced infarct size to 44 +/- 6% (n = 6) or 42 +/- 1% (n = 6), respectively. " 11/01/1995 - "4. We propose that a 1 h pretreatment of PGE1 or PGE0 reduces infarct size by activating protein kinase C resulting in the opening of KATP channels."
4.	Anovulation 04/01/1995 - "Anovulation was more frequent in subjects with TLE (35.3%) than in subjects with PGE (0%) or in controls (8.3%). "

Related Drugs and Biologics

1.	prostaglandin E0
2.	Alprostadil (Muse)
3.	KATP Channels
4.	Protein Kinase C
5.	Glyburide (Glibenclamide)

Related Therapies and Procedures

1.	Intravenous Administration